On the stock market since 2020, it operates in the world of health and science. It has 70 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 16% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $2.2M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 15 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $20.00 — 211% above today’s price.
A loss of $24.2M against $2.2M in annual sales. And on top of that, sales fell from the year before.
This stock swings about 2.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, ALGS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ALGS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (10/100) says the stock isn’t cheap.